Quadro Liquids Blog / Articles

Advantages of Wet Mill Micronization in Pharmaceutical Manufacturing

Published on Apr 7, 2021 3:01:44 PM

HV high shear homogenizer wet mill

This blog is brought to you by Regis Custom Pharma, a division of Regis Technologies, Inc. Particle size reduction techniques such as micronization are an essential feature in pharmaceutical manufacturing operations.

The Challenge - Particle Size Reduction

This blog looks at the challenges faced with Particle Size Reduction and poorly soluble drug compounds. Changing a compound’s particle size can alter a drug’s properties, affecting performance characteristics, stability, and downstream processability. Manufacturing techniques must be carefully chosen to avoid impacts on safety or efficacy.

Wet Mill Micronization

Mixing Heatmap Wet Mill Micronization is the ideal tool for controlled particle size reduction during API development and has many advantages over jet milling. Tailor-made for compounds vulnerable to the impacts of processing, wet-milling avoids the disadvantages of dry-micronization, such as presenting disorder into the milled crystalline API.

Find out how wet-milling at Regis Technologies, Inc. is performed as a ‘unit operation’ in the same location as the synthesis by checking out this video.

Quadro® HV high shear homogenizer

At Quadro® Liquids, the Quadro® HV high shear homogenizer series offers high shear results without the need for high-pressure processing and is ideally suited for processing submicron emulsions or suspension micronization. By providing more process shear energy than a conventional rotor-stator mill, capital costs are significantly lowered when compared to high-pressure homogenizer machines or media mills.

Learn more about our mixing equipment 

Contact us today to see discuss your liquid processing and powder dispersion challenges. Quadro Liquids are a leading manufacturer of High Shear Mixers with expertise across a range of Industries - our team is ready to help you with your mixing requirements.

New call-to-action
Posted by Matt Baumber
Find me on:

Topics: Pharmaceutical